TY - JOUR
T1 - PIEZO2 deficiency is a recognizable arthrogryposis syndrome
T2 - A new case and literature review
AU - Yamaguchi, Tomomi
AU - Takano, Kyoko
AU - Inaba, Yuji
AU - Morikawa, Manami
AU - Motobayashi, Mitsuo
AU - Kawamura, Rie
AU - Wakui, Keiko
AU - Nishi, Eriko
AU - Hirabayashi, Shin ichi
AU - Fukushima, Yoshimitsu
AU - Kato, Hiroyuki
AU - Takahashi, Jun
AU - Kosho, Tomoki
N1 - Funding Information:
We thank the patient and her parents for participating in this study. We are also grateful to Dr. Masashi Nakatani, Faculty of Environment and Information Studies, Keio University, for his critical instruction about basic function of PIEZO2. We thank Dr. Yasuyuki Miyake and Ms. Yuki Takahashi for technical assistance to molecular investigation, Ms. Masumi Ishikawa and Ms. Emiko Kise for patient care, and Mr. Benjamin Knight, MSc., from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. This work was supported by Practical Research Project for Rare/Intractable Diseases, Japan Agency for Medical Research and Development (AMED) (#105) (2015-7) (T.K.); Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#25460405) (2013-5) (T.K.); Research on Intractable Diseases, Ministry of Health, Labour and Welfare, Japan (#073) (2012-3) (T.K.); Medical Research Encouragement Prize of the Japan Medical Association (2013) (T.K.); Japan Foundation for Pediatric Research (2014) (T.K.); Program for an Integrated Database of Clinical and Genomic Information, Japan Agency for Medical Research and Development (AMED) (#16kk0205001h0501, #16kk0205012h1001) (2016–2020) (T.Y., K.T., K.W., Y.F., T.K.); Problem-Solving Oriented Training Program for Advanced Medical Personnel: NGSD Project (Y.F.); Pfizer Academic Contributions (AC180651) (T.K.)
Funding Information:
This work was supported by Practical Research Project for Rare/Intractable Diseases, Japan Agency for Medical Research and Development (AMED) (#105) (2015-7) (T.K.); Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#25460405) (2013-5) (T.K.); Research on Intractable Diseases, Ministry of Health, Labour and Welfare, Japan (#073) (2012-3) (T.K.); Medical Research Encouragement Prize of the Japan Medical Association (2013) (T.K.); Japan Foundation for Pediatric Research (2014) (T.K.); Program for an Integrated Database of Clinical and Genomic Information, Japan Agency for Medical Research and Development (AMED) (#16kk0205001h0501, #16kk0205012h1001) (2016–2020) (T.Y., K.T., K.W., Y.F., T.K.); Problem-Solving Oriented Training Program for Advanced Medical Personnel: NGSD Project (Y.F.); Pfizer Academic Contributions (AC180651) (T.K.)
Funding Information:
Japan Agency for Medical Research and Development, Grant/Award Number: Program for an Integrated Database of Clinical and; Japan Agency for Medical Research and Development , Grant/Award Number: Practical Research Project for Rare/Intractable Di; Japan Foundation for Pediatric Research; Ministry of Health, Labour and Welfare, Grant/Award Number: Research on Intractable Diseases/073; the Japan Medical Association, Grant/Award Number: Medical Research Encouragement Prize; the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grant/Award Number: Grant-in-Aid for Scientific Research (C)/25460405
Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2019/6
Y1 - 2019/6
N2 - PIEZO2 encodes a mechanically activated cation channel, which is abundantly expressed in dorsal root ganglion neuron and sensory endings of proprioceptors required for light touch sensation and proprioception in mice. Biallelic loss-of-function mutations in PIEZO2 (i.e., PIEZO2 deficiency) were recently found to cause an arthrogryposis syndrome. Sixteen patients from eight families have been reported to date. Herein we report a new case, including detailed clinical characteristics and courses as well as comprehensive neurological features. The patient was a 12-year-old girl presenting with congenital multiple contractures, progressive severe scoliosis, prenatal-onset growth impairment, motor developmental delay with hypotonia and myopathy-like muscle pathology, mild facial features, and normal intelligence. Her neurological features included areflexia, impaired proprioception, and decreased senses. Neurophysiological examination revealed decreased amplitude of sensory nerve action potentials, absent H reflex, and prolongation of central conduction times. Clinical exome sequencing revealed a novel homozygous frameshift mutation in PIEZO2 (NM_022068: c.4171_4174delGTCA: p.Val1391Lysfs*39) with no detectable mRNA expression of the gene. PIEZO2 deficiency represents a clinical entity involving characteristic neuromuscular abnormalities and physical features. Next generation sequencing-based comprehensive molecular screening and extensive neurophysiological examination could be valuable for diagnosis of the disorder.
AB - PIEZO2 encodes a mechanically activated cation channel, which is abundantly expressed in dorsal root ganglion neuron and sensory endings of proprioceptors required for light touch sensation and proprioception in mice. Biallelic loss-of-function mutations in PIEZO2 (i.e., PIEZO2 deficiency) were recently found to cause an arthrogryposis syndrome. Sixteen patients from eight families have been reported to date. Herein we report a new case, including detailed clinical characteristics and courses as well as comprehensive neurological features. The patient was a 12-year-old girl presenting with congenital multiple contractures, progressive severe scoliosis, prenatal-onset growth impairment, motor developmental delay with hypotonia and myopathy-like muscle pathology, mild facial features, and normal intelligence. Her neurological features included areflexia, impaired proprioception, and decreased senses. Neurophysiological examination revealed decreased amplitude of sensory nerve action potentials, absent H reflex, and prolongation of central conduction times. Clinical exome sequencing revealed a novel homozygous frameshift mutation in PIEZO2 (NM_022068: c.4171_4174delGTCA: p.Val1391Lysfs*39) with no detectable mRNA expression of the gene. PIEZO2 deficiency represents a clinical entity involving characteristic neuromuscular abnormalities and physical features. Next generation sequencing-based comprehensive molecular screening and extensive neurophysiological examination could be valuable for diagnosis of the disorder.
UR - http://www.scopus.com/inward/record.url?scp=85063813704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063813704&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.61142
DO - 10.1002/ajmg.a.61142
M3 - Article
C2 - 30941898
AN - SCOPUS:85063813704
SN - 1552-4825
VL - 179
SP - 948
EP - 957
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 6
ER -